Insider · CIK 0001916940
Gilbert Lynn Marks
director
Files at ANTX (AN2 Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,665 | - | - | 10,665 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -10,665 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,362 | - | - | 10,362 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -10,362 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +23,742 | - | - | 23,742 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -23,742 | - | - | 0 | Mar 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Feb 23, 2026 |
| Jan 12, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +11,560 | $0.00 | $0 | 75,309 | Jan 14, 2026 |
| Oct 10, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +10,367 | $0.00 | $0 | 63,749 | Oct 14, 2025 |
| Jul 10, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +11,875 | $0.00 | $0 | 53,382 | Jul 11, 2025 |
| May 22, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| Apr 10, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +9,705 | $0.00 | $0 | 41,507 | Apr 11, 2025 |
| Dec 19, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +8,972 | $0.00 | $0 | 31,802 | Dec 23, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.